Gemopatrilat Explained

Gemopatrilat (INN)[1] is an experimental drug that was never marketed.[2] It acts as a vasopeptidase inhibitor.[3] [4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).[5]

Notes and References

  1. Web site: International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46 . World Health Organization . 2 March 2017 . 200.
  2. Web site: Gemopatrilat . AdisInsight . Highest Development Phases: Discontinued.
  3. Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G . January 2003 . Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes . Kidney International . 63 . 1 . 64–71 . 10.1046/j.1523-1755.2003.00708.x . 12472769 . free.
  4. Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA . 6 . Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans . Drug Metabolism and Disposition . 34 . 6 . 961–70 . June 2006 . 16540589 . 10.1124/dmd.105.007500 . 25629874 .
  5. Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM . In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat . Journal of Hypertension . 19 . 5 . 941–6 . May 2001 . 11393678 . 10.1097/00004872-200105000-00015 . 9162678 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Gemopatrilat".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.